Top Markets
#1 Black Phoenix Black Phoenix +827.77%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +27.70%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.17%
#4 Bless Bless +22.57%
#5 pipedog pipedog +22.16%
#6 SAFEcoin SAFEcoin +20.09%
#7 Beam Beam +19.57%
#8 Magma Finance Magma Finance +19.26%
#9 PondCoin PondCoin +18.66%
#10 YFSX YFSX +15.99%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Zymeworks Inc. Zymeworks Inc.

Zymeworks Inc.

ZYME
Classifica tra le azioni #6233
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase,... Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Prezzo delle azioni
$29.33
Capitalizzazione di mercato
$2.16B
Variazione (1 giorno)
0.07%
Variazione (1 anno)
96.42%
Paese
US
Scambia Zymeworks Inc. (ZYME)

Categoria

Healthcare
Utile per Zymeworks Inc. (ZYME)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Zymeworks Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Zymeworks Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH